Biohaven Pharmaceutical Holding Co. Ltd.(NYSE : BHVN)
BHVN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-1.88%||162.11||0.7%||$1086.81m|
|MRK||Merck & Co., Inc.||-0.79%||76.62||0.7%||$1018.44m|
|LLY||Eli Lilly & Co.||-1.68%||218.47||1.1%||$906.20m|
|BMY||Bristol-Myers Squibb Co.||-0.34%||66.54||1.0%||$643.98m|
|ANVS||Annovis Bio, Inc.||2.78%||92.55||0.0%||$317.09m|
|CNST||Constellation Pharmaceuticals, Inc.||-0.18%||33.76||0.0%||$107.09m|
Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.